Penetration of diazepam and the non-peptide CCK antagonist, L-364, 718, into rat brain

Abstract

Abstract Interest in the actions of the peptide cholecystokinin (CCK) has led to the design and synthesis of several non-peptide CCK antagonists, the most recent being that produced by Merck Sharp & Dohme and designated L-364, 718. This can be viewed as modified D-tryptophan linked to diazepam (1-methyl-3-(2-indoloyl)amino-5-phenyl-3H-1,4-benzodiazepin-2-one) 1.